We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
REVIEW
Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis.
BACKGROUND: Inflammation biomarkers have been introduced into clinical practice for risk-rating in treatment of patients with cancer. We aimed to confirm the prognostic role of platelet-to-lymphocyte ratio (PLR) as a powerful biomarker for patients with advanced cancer.
METHOD: A systematic literature search was conducted through PubMed, Embase and Web of Science databases for studies on advanced tumors. Research articles that analyzed the PLR and hazard ratios (HR) in patients with overall survival (OS) or progression-free survival (PFS) data were involved. Two authors assessed the eligibility of trials and extracted data independently. Meta-analyses were performed with random-effect models. Data heterogeneity was calculated with the I2 method.
RESULTS: Thirty-three eligible cohort studies including 8215 patients were further analyzed. Elevated PLR was associated with reduced OS (HR = 1.45, 95% CI, 1.31-1.61, p < 0.001) and PFS (HR = 1.73, 95% CI, 1.31-2.29, p < 0.001) in patients with advanced cancer. A extreme result was observed in a subgroup analysis in metastatic renal cancer with the worst OS (HR = 2.47, 95% CI, 1.32-4.62, p = .005) and PFS (HR = 3.89, 95% CI, 1.23-12.28, p = 0.021).
CONCLUSIONS: Patients with high pretreatment blood PLR level have poor OS and PFS. Further investigations are needed to explore the underlying mechanisms.
METHOD: A systematic literature search was conducted through PubMed, Embase and Web of Science databases for studies on advanced tumors. Research articles that analyzed the PLR and hazard ratios (HR) in patients with overall survival (OS) or progression-free survival (PFS) data were involved. Two authors assessed the eligibility of trials and extracted data independently. Meta-analyses were performed with random-effect models. Data heterogeneity was calculated with the I2 method.
RESULTS: Thirty-three eligible cohort studies including 8215 patients were further analyzed. Elevated PLR was associated with reduced OS (HR = 1.45, 95% CI, 1.31-1.61, p < 0.001) and PFS (HR = 1.73, 95% CI, 1.31-2.29, p < 0.001) in patients with advanced cancer. A extreme result was observed in a subgroup analysis in metastatic renal cancer with the worst OS (HR = 2.47, 95% CI, 1.32-4.62, p = .005) and PFS (HR = 3.89, 95% CI, 1.23-12.28, p = 0.021).
CONCLUSIONS: Patients with high pretreatment blood PLR level have poor OS and PFS. Further investigations are needed to explore the underlying mechanisms.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app